Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen

Jade Ghosn, Giampiero Carosi, Santiago Moreno, Vadim Pokrovsky, Adriano Lazzarin, Gilles Pialoux, Jose Sanz-Moreno, Agnes Balogh, Eric Vandeloise, Sophie Biguenet, Ghislaine Leleu, Jean Francois Delfraissy

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Triple combination therapy based on a ritonavir (RTV)-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) has improved outcomes in HIV type-1 (HIV-1)-infected patients. For patients unable to tolerate these regimens, alternative therapeutic approaches are needed. Methods: We report a comparative, open-label study in treatment-naive patients who underwent initial induction treatment with a triple combination including RTV-boosted atazanavir (ATV; 300/100 mg once daily). Patients who achieved an HIV-1 viral load + T-cell counts were also similar between the treatment arms. Although both regimens were well-tolerated, unboosted ATV was associated with fewer adverse events, fewer total bilirubin abnormalities and an improved lipid profile compared with ATV/RTV. Conclusions: An HIV-1 combined treatment regimen based on unboosted ATV is a feasible treatment option for patients with established virological control who are unable to tolerate triple combination therapy including ATV/RTV.

Original languageEnglish
Pages (from-to)993-1002
Number of pages10
JournalAntiviral Therapy
Volume15
Issue number7
DOIs
Publication statusPublished - 2010

Fingerprint

Ritonavir
HIV-1
Therapeutics
Reverse Transcriptase Inhibitors
Atazanavir Sulfate
Protease Inhibitors
Viral Load
Bilirubin
Nucleosides
Nucleotides
Cell Count
T-Lymphocytes
Lipids

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Ghosn, J., Carosi, G., Moreno, S., Pokrovsky, V., Lazzarin, A., Pialoux, G., ... Delfraissy, J. F. (2010). Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antiviral Therapy, 15(7), 993-1002. https://doi.org/10.3851/IMP1666

Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. / Ghosn, Jade; Carosi, Giampiero; Moreno, Santiago; Pokrovsky, Vadim; Lazzarin, Adriano; Pialoux, Gilles; Sanz-Moreno, Jose; Balogh, Agnes; Vandeloise, Eric; Biguenet, Sophie; Leleu, Ghislaine; Delfraissy, Jean Francois.

In: Antiviral Therapy, Vol. 15, No. 7, 2010, p. 993-1002.

Research output: Contribution to journalArticle

Ghosn, J, Carosi, G, Moreno, S, Pokrovsky, V, Lazzarin, A, Pialoux, G, Sanz-Moreno, J, Balogh, A, Vandeloise, E, Biguenet, S, Leleu, G & Delfraissy, JF 2010, 'Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen', Antiviral Therapy, vol. 15, no. 7, pp. 993-1002. https://doi.org/10.3851/IMP1666
Ghosn, Jade ; Carosi, Giampiero ; Moreno, Santiago ; Pokrovsky, Vadim ; Lazzarin, Adriano ; Pialoux, Gilles ; Sanz-Moreno, Jose ; Balogh, Agnes ; Vandeloise, Eric ; Biguenet, Sophie ; Leleu, Ghislaine ; Delfraissy, Jean Francois. / Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. In: Antiviral Therapy. 2010 ; Vol. 15, No. 7. pp. 993-1002.
@article{eec23bd98db14978b721121457cc31af,
title = "Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen",
abstract = "Background: Triple combination therapy based on a ritonavir (RTV)-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) has improved outcomes in HIV type-1 (HIV-1)-infected patients. For patients unable to tolerate these regimens, alternative therapeutic approaches are needed. Methods: We report a comparative, open-label study in treatment-naive patients who underwent initial induction treatment with a triple combination including RTV-boosted atazanavir (ATV; 300/100 mg once daily). Patients who achieved an HIV-1 viral load + T-cell counts were also similar between the treatment arms. Although both regimens were well-tolerated, unboosted ATV was associated with fewer adverse events, fewer total bilirubin abnormalities and an improved lipid profile compared with ATV/RTV. Conclusions: An HIV-1 combined treatment regimen based on unboosted ATV is a feasible treatment option for patients with established virological control who are unable to tolerate triple combination therapy including ATV/RTV.",
author = "Jade Ghosn and Giampiero Carosi and Santiago Moreno and Vadim Pokrovsky and Adriano Lazzarin and Gilles Pialoux and Jose Sanz-Moreno and Agnes Balogh and Eric Vandeloise and Sophie Biguenet and Ghislaine Leleu and Delfraissy, {Jean Francois}",
year = "2010",
doi = "10.3851/IMP1666",
language = "English",
volume = "15",
pages = "993--1002",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "7",

}

TY - JOUR

T1 - Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen

AU - Ghosn, Jade

AU - Carosi, Giampiero

AU - Moreno, Santiago

AU - Pokrovsky, Vadim

AU - Lazzarin, Adriano

AU - Pialoux, Gilles

AU - Sanz-Moreno, Jose

AU - Balogh, Agnes

AU - Vandeloise, Eric

AU - Biguenet, Sophie

AU - Leleu, Ghislaine

AU - Delfraissy, Jean Francois

PY - 2010

Y1 - 2010

N2 - Background: Triple combination therapy based on a ritonavir (RTV)-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) has improved outcomes in HIV type-1 (HIV-1)-infected patients. For patients unable to tolerate these regimens, alternative therapeutic approaches are needed. Methods: We report a comparative, open-label study in treatment-naive patients who underwent initial induction treatment with a triple combination including RTV-boosted atazanavir (ATV; 300/100 mg once daily). Patients who achieved an HIV-1 viral load + T-cell counts were also similar between the treatment arms. Although both regimens were well-tolerated, unboosted ATV was associated with fewer adverse events, fewer total bilirubin abnormalities and an improved lipid profile compared with ATV/RTV. Conclusions: An HIV-1 combined treatment regimen based on unboosted ATV is a feasible treatment option for patients with established virological control who are unable to tolerate triple combination therapy including ATV/RTV.

AB - Background: Triple combination therapy based on a ritonavir (RTV)-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) has improved outcomes in HIV type-1 (HIV-1)-infected patients. For patients unable to tolerate these regimens, alternative therapeutic approaches are needed. Methods: We report a comparative, open-label study in treatment-naive patients who underwent initial induction treatment with a triple combination including RTV-boosted atazanavir (ATV; 300/100 mg once daily). Patients who achieved an HIV-1 viral load + T-cell counts were also similar between the treatment arms. Although both regimens were well-tolerated, unboosted ATV was associated with fewer adverse events, fewer total bilirubin abnormalities and an improved lipid profile compared with ATV/RTV. Conclusions: An HIV-1 combined treatment regimen based on unboosted ATV is a feasible treatment option for patients with established virological control who are unable to tolerate triple combination therapy including ATV/RTV.

UR - http://www.scopus.com/inward/record.url?scp=78651113527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651113527&partnerID=8YFLogxK

U2 - 10.3851/IMP1666

DO - 10.3851/IMP1666

M3 - Article

C2 - 21041914

AN - SCOPUS:78651113527

VL - 15

SP - 993

EP - 1002

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 7

ER -